MedTrace Logo

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

NCT06531447 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-08-01

No results posted yet for this study

Summary

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Conditions

Interventions

DRUG

Cisplatin

Every 21 days 6 cycles

DRUG

Gemcitabine

Every 21 days (First and 8th days) 6 cycles

DRUG

Doxorubicin

Every 21 days 4 cycles

DRUG

Cyclophosphamide

Every 21 days 4 cycles

DRUG

Paclitaxel

Every 21 days 4 cycles or once a week for 12 weeks

Sponsors & Collaborators

  • The National Center of Oncology, Azerbaijan

    lead OTHER_GOV

Principal Investigators

  • Elchin Mansurov, PhD · The National Center of Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-11-30
Completion
2027-05-31

Countries

  • Azerbaijan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531447 on ClinicalTrials.gov